agreed. Really agree with all of what kervio said, but the key point here is we are looking at a clinical unmet medical need for children with a relatively high mortality rate. If this were not an unment medical need (i.e. there were already options available for these children) then id say definitely FDA will be staunch on their opinion, but we have a good case with nothing else on the market (acellerated approval conditional with adult RCT) AND its completely safe (basically patients have nothing to lose) and manufacturing seems to be fine.
- Forums
- ASX - By Stock
- MSB
- MSB to dispute FDA finding in Type A meeting
MSB to dispute FDA finding in Type A meeting, page-364
-
- There are more pages in this discussion • 654 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.324B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $4.360M | 3.696M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
35 | 30486 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 14547 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 14417 | 1.165 |
34 | 53676 | 1.160 |
13 | 36820 | 1.155 |
15 | 114053 | 1.150 |
17 | 208918 | 1.145 |
Price($) | Vol. | No. |
---|---|---|
1.170 | 77478 | 9 |
1.175 | 73011 | 11 |
1.180 | 77071 | 11 |
1.185 | 13924 | 3 |
1.190 | 44000 | 4 |
Last trade - 14.07pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online